19-1207093-C-G
Position:
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000455.5(STK11):c.180C>G(p.Tyr60*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: not found (cov: 31)
Consequence
STK11
NM_000455.5 stop_gained
NM_000455.5 stop_gained
Scores
2
2
3
Clinical Significance
Conservation
PhyloP100: -0.100
Genes affected
STK11 (HGNC:11389): (serine/threonine kinase 11) The protein encoded by this gene is a serine/threonine kinase that regulates cell polarity and energy metabolism and functions as a tumor suppressor. Mutations in this gene have been associated with the autosomal dominant Peutz-Jeghers syndrome, as well as with skin, pancreatic, and testicular cancers. [provided by RefSeq, May 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 19-1207093-C-G is Pathogenic according to our data. Variant chr19-1207093-C-G is described in ClinVar as [Pathogenic]. Clinvar id is 428749.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr19-1207093-C-G is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
STK11 | NM_000455.5 | c.180C>G | p.Tyr60* | stop_gained | 1/10 | ENST00000326873.12 | NP_000446.1 | |
STK11 | NM_001407255.1 | c.180C>G | p.Tyr60* | stop_gained | 1/9 | NP_001394184.1 | ||
STK11 | NR_176325.1 | n.1316C>G | non_coding_transcript_exon_variant | 1/11 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
STK11 | ENST00000326873.12 | c.180C>G | p.Tyr60* | stop_gained | 1/10 | 1 | NM_000455.5 | ENSP00000324856.6 | ||
STK11 | ENST00000652231.1 | c.180C>G | p.Tyr60* | stop_gained | 1/9 | ENSP00000498804.1 | ||||
STK11 | ENST00000585748.3 | c.-82-11324C>G | intron_variant | 3 | ENSP00000477641.2 | |||||
STK11 | ENST00000593219.5 | n.180C>G | non_coding_transcript_exon_variant | 1/4 | 3 | ENSP00000466610.1 |
Frequencies
GnomAD3 genomes Cov.: 31
GnomAD3 genomes
Cov.:
31
GnomAD4 exome Cov.: 31
GnomAD4 exome
Cov.:
31
GnomAD4 genome Cov.: 31
GnomAD4 genome
Cov.:
31
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:5
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Peutz-Jeghers syndrome Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein | Jul 05, 2022 | ACMG classification criteria: PVS1 very strong, PS4 strong, PM2 moderated, PP1 supporting - |
Pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Feb 09, 2024 | This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation. - |
Pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Jul 15, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 14, 2020 | This variant has been observed in several individuals affected with Peutz-Jeghers syndrome (PJS) (PMID: 9428765, 24604241, 11389158), and has been shown to segregate with PJS in one family (PMID: 17637250). ClinVar contains an entry for this variant (Variation ID: 428749). For these reasons, this variant has been classified as Pathogenic. Loss-of-function variants in STK11 are known to be pathogenic (PMID: 15188174, 16287113). This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Tyr60*) in the STK11 gene. It is expected to result in an absent or disrupted protein product. - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 18, 2020 | The p.Y60* pathogenic mutation (also known as c.180C>G) located in coding exon 1 of the STK11 gene, results from a C to G substitution at nucleotide position 180. This changes the amino acid from a tyrosine to a stop codon within coding exon 1. This mutation has been reported in numerous individuals/families with a clinical diagnosis of Peutz-Jeghers syndrome (Hemminki A et al. Nature.1998 Jan 8;391(6663):184-7; Olschwang S et al. J Med Genet. 2001 Jun;38(6):356-60; Lim W et al. Gastroenterology. 2004 Jun;126(7):1788-94; Dai L et al. Dig Dis Sci. 2014 Mar 7). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
Eigen
Uncertain
Eigen_PC
Benign
FATHMM_MKL
Benign
D
Vest4
GERP RS
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at